Barclays’s AYTU BioPharma AYTU Stock Holding History

Barclays’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$2	–	5246
2025 Q3	$2	Hold	1	–	–	﹤0.01%	5429
2025 Q2	$2	Hold	1	–	–	﹤0.01%	5182
2025 Q1	$1	Buy	+1	New	+$1	﹤0.01%	5223
2023 Q1	–	Hold	0	–	–	–	5084
2022 Q4	–	Hold	0	–	–	–	5267
2022 Q3	–	Hold	0	–	–	–	4781
2022 Q2	–	Hold	0	–	–	–	5018
2022 Q1	–	Hold	0	–	–	–	4943
2020 Q4	–	Sell	-53	Closed	-$12K	–	4867
2020 Q3	$12K	Sell	53 -10	-16%	-$2.57K	﹤0.01%	4972
2020 Q2	$18K	Buy	+63	New	+$19.1K	﹤0.01%	5218
2020 Q1	–	Hold	0	–	–	–	6131
2019 Q4	–	Hold	0	–	–	–	6342
2019 Q3	–	Hold	0	–	–	–	6703
2019 Q2	–	Hold	0	–	–	–	6935
2019 Q1	–	Hold	0	–	–	–	7005
2018 Q4	–	Hold	0	–	–	–	6930
2018 Q3	–	Hold	0	–	–	–	7112
2018 Q2	–	Hold	0	–	–	–	6960
2018 Q1	–	Hold	0	–	–	–	7048
2017 Q4	–	Hold	0	–	–	–	6917

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Barclays's AYTU Position: Q4 2025 in Review

Barclays sold out of AYTU BioPharma (AYTU) in Q4 2025, closing a stake of 1 share — an estimated $2 sold.

Barclays first reported a position in AYTU in Q2 2020 and held it in 5 quarters. The position peaked at $18K in Q2 2020. 39 funds tracked by Wall St. Rank hold AYTU as of Q4 2025.

Barclays reported no remaining AYTU BioPharma position as of Q4 2025 after selling out during the quarter.
Barclays sold 1 AYTU BioPharma share in Q4 2025, an estimated $2.
Barclays first reported a position in AYTU BioPharma in Q2 2020 and held it in 5 quarters.
Barclays's AYTU BioPharma position peaked at $18K in Q2 2020.
39 funds tracked by Wall St. Rank held AYTU BioPharma as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.